Advice for Healthcare Professionals The MHRA Drug Safety Update provides the following key guidance for healthcare professionals: Semaglutide treatment may be very rarely associated with NAION, which can cause vision loss, typically in one eye NAION typically presents as sudden, painless vision loss described as blurring or cloudiness Privately prescribed semaglutide may not appear on a patients medical record if a patient presents with these symptoms, enquire about semaglutide use Patients reporting sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist Discontinue semaglutide treatment if NAION is confirmed Advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience sudden vision loss or rapidly worsening eyesight An alert advised healthcare professionals to be vigilant for further issues, including rare but serious side effects such as acute pancreatitis
Expected Results Timeline Weeks 14 During the first month, many users notice improved hydration, reduced redness, and slightly firmer skin
Biotin (from culture of S cerevisiae)
Combining biomarker assessment with genetic predisposition data allows you and your provider to move beyond one-size-fits-all supplementation
Neil K Gibbs, L-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema), The Journal of Nutrition , Volume 150, Issue Supplement_1, October 2020, Pages 2576S2579S, Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H
